

Aspirin Not Cardioprotective in Type 2 Diabetes

BY CAROLINE HELWICK
Contributing Writer

NEW ORLEANS — Aspirin therapy is commonly used for primary prevention of cardiovascular events in persons with type 2 diabetes, but a Japanese study of 2,539 subjects found no statistically significant reduction in the primary end point of total atherosclerotic events, except in patients aged at least 65 years.

The study, which is the largest primary prevention trial of aspirin in type 2 diabetes, was reported at the annual scientific sessions of the American Heart Association.

In the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial, the use of daily low-dose aspirin was associated with a 20% non-significant reduction in the risk of the

In the Japanese study, daily low-dose aspirin was associated with an insignificant reduction in coronary, cerebrovascular, and peripheral vascular events.

combined end point of coronary, cerebrovascular, and peripheral vascular events in the population as a whole, and a 32% statistically significant reduction in events among those aged 65 and older, reported Dr. Hisao

Ogawa of the Kumamoto (Japan) University.

Aspirin use also significantly reduced the composite of fatal coronary and fatal cerebrovascular events.

“Although the effect of low-dose aspirin was not statistically significant for the primary end point, a significant effect was demonstrated on fatal coronary and fatal cerebrovascular events. The trial also suggests that low-dose aspirin might reduce total events in older patients,” he said at a late-breaking trials session.

The results were reported online simultaneously with Dr. Ogawa’s presentation (JAMA 2008;300:2134-41).

Japanese investigators from 163 institutions examined the benefit of low-dose aspirin for preventing cardiovascular events in 2,539 patients with type 2 diabetes who had no history of atherosclerotic disease. Average age of the patients was 65 years and 55% were men. Patients were randomly assigned to receive 81-100 mg aspirin per day (n = 1,262) or no aspirin (n = 1,277). The primary end point was the composite of all coronary, cerebrovascular, and peripheral vascular events.

After a median follow-up of 4.4 years, a total of 154 fatal and nonfatal atherosclerotic events had occurred: 68 in the aspirin group and 86 in the nonaspirin group. This represented a rate of 13.6 vs. 17.0 events per 1,000 person-years, for a 20% reduction in risk that was not statistically significant, Dr. Ogawa reported.

Benefit was, however, demonstrated in older patients taking aspirin. Among the 719 patients aged at least 65 in the aspirin arm, 45 events (6.3%) atherosclerotic events occurred, compared with 59 events (9.2%)

in the 644 older patients in the nonaspirin group, representing a statistically significant 32% reduction in risk with aspirin use.

The combined secondary end point of fatal coronary events and fatal cerebrovascular events occurred in 1 patient (stroke) in the aspirin group and 10 patients (5 fatal myocardial infarctions and 5 fatal strokes) in the nonaspirin group, for a 90% statistically significant reduction in risk for that outcome.

Adverse effects occurred in 86 persons

taking aspirin and 14 not on aspirin. Hemorrhagic events were greater with aspirin (34 vs. 10), including an increase in gastrointestinal bleeding and the need for transfusion for severe GI bleeding in four patients, but there was no increase in hemorrhagic stroke.

“JPAD supports the safety of using low-dose aspirin in diabetics for primary prevention,” he said.

The investigators cautioned that the findings should be interpreted in context


of the low incidence of atherosclerotic disease in Japan and the aggressive management of cardiovascular risk factors. “The event rate was lower than anticipated because the patients were so well treated,” Dr. Ogawa said. “They saw their physicians every 2-4 weeks.”

Dr. Marian Limacher, professor of medicine at the University of Florida, Gainesville, said JPAD was “a well-designed and well-conducted study” that aimed to address a question that “some

NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important safety information

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. **When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent.** Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins. Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity. Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy.



Model is for illustrative purposes only.



FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S.
©2008 Novo Nordisk Inc. 136405

October 2008

may have thought did not need to be answered," given the widespread recommendation for the use of aspirin in diabetic patients. "However, the evidence basis for this has been lacking until recently, and JPAD adds to this considerably," she commented at a press conference.

The findings are congruent with the recently completed Progression of Arterial Disease and Diabetes (POPADAD) study from Great Britain, she noted. POPADAD, involving 1,276 patients with asymptomatic peripheral arterial disease, found no evidence for aspirin's benefit on cardiovascular events and mortality.

As discussant of the paper, Dr. Limach-

er offered several possible explanations for the lack of effect on the primary end point, including the choice of population, which involved a number of percentage of women who may respond differently to aspirin than do men; the dose, which may have been too low to be protective in some patients; a too-short duration of intervention; the effect of aspirin resistance in some patients; the use of concomitant risk factor-modifying medications; and lack of power to show an effect when event rates were so low.

"We may need to rethink the guidelines," she suggested, "especially for patients younger than 65." ■

Get Your **FREE** Online Copy of
Clinical Endocrinology News

Go to
www.clinicalendocrinologynews.com
for your monthly online edition.

Access is free and your e-mail privacy is ensured.
Enjoy full-text search and links to our medical specialty newspapers.

Take on the mealtime challenge

NovoLog® helps put glycemic control within reach by managing mealtime glucose. Not only that, **NovoLog® is proven to help a wide variety of patients get to the next level of treatment:**

- Adults with type 1 diabetes
- Adults with type 2 diabetes
- Children and adolescents with type 1 diabetes
- Pump users (adults and children/adolescents)
- Geriatric patients
- Pregnant women (Category B)

To access complimentary e-learning programs, visit novomedlink.com/NovoLog.



NovoLog®
insulin aspart (rDNA origin) injection